



Published in final edited form as:

Ann Oncol. 2021 February ; 32(2): 197–207. doi:10.1016/j.annonc.2020.10.596.

Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, *PIK3CA*-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial[★]

S. Dent^{1,†}, J. Cortés^{2,3,‡}, Y.-H. Im⁴, V. Diéras^{5,6}, N. Harbeck⁷, I. E. Krop⁸, T. R. Wilson⁹, N. Cui^{9,§}, F. Schimmoller⁹, J. Y. Hsu⁹, J. He^{9,¶}, M. De Laurentiis¹⁰, S. Sousa¹¹, P. Drullinsky¹², W. Jacot^{13,*}

¹The Ottawa Hospital Cancer Centre, Ottawa, Canada

²IOB Institute of Oncology, Quiron Group, Madrid & Barcelona

³Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

⁴Samsung Medical Center, Seoul, Republic of Korea

⁵Institut Curie, Paris

⁶Centre Eugène Marquis, Rennes, France

⁷Breast Center, Department Gynecology and Obstetrics and CCC Munich, LMU University Hospital, Munich, Germany

⁸Dana-Farber Cancer Institute, Boston, USA

⁹Genentech, Inc., South San Francisco, USA

¹⁰IRCCS Istituto Nazionale Tumori “Fondazione G. Pascale”, Naples, Italy

¹¹Instituto Português de Oncologia do Porto Francisco Gentil, Porto, Portugal

¹²Memorial Sloan Kettering Cancer Center, Memorial Hospital, New York, USA

¹³Institut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier University, Montpellier, France

★Note: This study was previously presented as trials in progress posters for SANDPIPER at the American Society of Clinical Oncology (ASCO) Congress 2015 (29 May to 2 June 2015), San Antonio Breast Cancer Symposium (SABCS) Congress 2015 (8–12 December 2015), ASCO Congress 2016 (3–7 June 2016), European Society for Medical Oncology (ESMO) Congress 2016 (7–11 October 2016), SABCS Congress 2016 (6–10 December 2016) and ASCO Congress 2017 (2–6 June 2017). Key data from SANDPIPER were presented in an oral session at the ASCO Congress 2018 (1–5 June 2018).

*Correspondence to: Prof. William Jacot, Medical Oncology Department, Institut Régional du Cancer de Montpellier (ICM), 208, Rue des Apothicaires, 34298 Montpellier, France. Tel: +33-4-67-61-23-39, Fax: +33-4-67-61-37-64, william.jacot@icm.unicancer.fr (W. Jacot).

[†]Present address: Duke Cancer Institute, Durham, NC, USA.

[‡]Present address: IBCC International Breast Cancer Center, Quiron Group, Barcelona.

[§]Present address: AstraZeneca, Zhangjiang Park, Shanghai, China.

[¶]Present address: CStone Pharmaceuticals (Suzhou) Co. Ltd, Suzhou, China.

DATA SHARING

Qualified researchers may request access to individual patient-level data through the clinical study data request platform (<https://vivli.org/>). Further details on Roche's criteria for eligible studies are available here (<https://vivli.org/members/ourmembers/>). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

Abstract

Background: The phase III SANDPIPER study assessed taselelisib (GDC-0032), a potent, selective PI3K inhibitor, plus fulvestrant in estrogen receptor-positive, HER2-negative, *PIK3CA*-mutant locally advanced or metastatic breast cancer.

Patients and methods: Postmenopausal women with disease recurrence/progression during/after an aromatase inhibitor were randomized 2 : 1 to receive taselelisib (4 mg; taselelisib arm) or placebo (placebo arm) plus fulvestrant (500 mg). Stratification factors were visceral disease, endocrine sensitivity, and geographic region. Patients with *PIK3CA*-mutant tumors (central cobas® *PIK3CA* Mutation Test) were randomized separately from those without detectable mutations. The primary endpoint was investigator-assessed progression-free survival (INV-PFS) in patients with *PIK3CA*-mutant tumors. Secondary endpoints included objective response rate, overall survival, clinical benefit rate, duration of objective response, PFS by blinded independent central review (BICR-PFS), safety, and time to deterioration in health-related quality of life.

Results: The *PIK3CA*-mutant intention-to-treat population comprised 516 patients (placebo arm: $n = 176$; taselelisib arm: $n = 340$). INV-PFS was significantly improved in the taselelisib {7.4 months [95% confidence interval (CI), 7.26-9.07]} versus placebo arm (5.4 months [95% CI, 3.68-7.29]) (stratified hazard ratio [HR] 0.70; 95% CI, 0.56-0.89; $P = 0.0037$) and confirmed by BICR-PFS (HR 0.66). Secondary endpoints, including objective response rate, clinical benefit rate, and duration of objective response, showed consistent improvements in the taselelisib arm. Safety was assessed in all randomized patients who received at least one dose of taselelisib/placebo or fulvestrant regardless of *PIK3CA*-mutation status ($n = 629$). Serious adverse events were lower in the placebo versus taselelisib arm (8.9% versus 32.0%). There were more discontinuations (placebo arm: 2.3%; taselelisib arm: 16.8%) and dose reductions (placebo arm: 2.3%; taselelisib arm: 36.5%) in the taselelisib arm.

Conclusion: SANDPIPER met its primary endpoint; however, the combination of taselelisib plus fulvestrant has no clinical utility given its safety profile and modest clinical benefit.

Keywords

PIK3CA mutations; taselelisib; PI3K inhibitors; advanced breast cancer

INTRODUCTION

The phosphatidylinositol 3-kinase (PI3K) pathway is involved in tumor growth, proliferation, and survival and is activated frequently in solid tumors.¹ Mechanisms activating this pathway include gain-of-function mutations and/or amplification of the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*) gene.¹⁻⁵ *PIK3CA* encodes the α -isoform of the catalytic subunit of PI3K (PI3K α)² and mutations are detected in ~40% of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancers (BCs).⁶ Preclinical data have demonstrated significant crosstalk between ER and PI3K pathways, and inhibition of PI3K results in an adaptive upregulation of ER signaling.^{7,8} Additionally, PI3K inhibition augments ER function and dependence in hormone receptor-positive BC.^{7,8}

Taselisib (GDC-0032), a potent, selective inhibitor of class I PI3K α -, δ -, and γ -isoforms,⁹⁻¹² has greater efficacy *in vitro* against mutant PI3K α isoforms and cells than those with wildtype PI3K α .^{9-11,13} A phase I study of single-agent taselisib suggested activity in *PIK3CA*-mutant BC.¹³ The safety profile was tolerable, with expected PI3K inhibitor class adverse events (AEs), including hyperglycemia, diarrhea, rash, and stomatitis.¹³⁻¹⁶ In a single-arm phase II study, response rates were higher in patients with *PIK3CA*-mutated advanced BC treated with taselisib plus fulvestrant than those with *PIK3CA*-mutation-not-detected (MND) tumors.¹⁷ In the neoadjuvant LORELEI study, taselisib plus letrozole (versus placebo plus letrozole) had a significantly improved objective response rate (ORR) in the ER-positive, HER2-negative intention-to-treat population; this was more pronounced in the *PIK3CA*-mutant population.¹⁸

The phase III SANDPIPER study (ClinicalTrials.gov: NCT02340221) aimed to assess the clinical efficacy of taselisib plus fulvestrant versus placebo plus fulvestrant in patients with ER-positive, HER2-negative, *PIK3CA*-mutant locally advanced or metastatic BC. An exploratory evaluation in patients with *PIK3CA*-MND tumors was also carried out.

PATIENTS AND METHODS

Study design and patients

SANDPIPER was a phase III, randomized, multicenter, international, double-blind, placebo-controlled trial (Supplementary Figure S1 available at <https://doi.org/10.1016/j.annonc.2020.10.596>). Patients received 500 mg intramuscular fulvestrant (cycle 1, days 1 and 15; day 1 of each subsequent 28-day cycle) plus either taselisib (the taselisib arm) or placebo (the placebo arm) until progressive disease or unacceptable toxicity. Patients received either 4 mg taselisib tablets orally, once daily, or matching placebo. Dose interruptions and reductions of taselisib or placebo were permitted for treatment-related toxicities (Supplementary Table S1 available at <https://doi.org/10.1016/j.annonc.2020.10.596>). Fulvestrant dose interruptions, but not reductions, were permitted. Patients discontinued study drugs if they experienced any medical condition that the investigator/sponsor determined may jeopardize patient safety, radiographic progressive disease (or clinical progression at the discretion of the investigator), unacceptable toxicity, or if they were not compliant with protocol-specified drug administration and follow-up tests, or if they withdrew consent. Study procedures are provided in the published protocol.

Eligible patients, enrolled at 155 centers in 28 countries (Supplementary Protocol available at <https://doi.org/10.1016/j.annonc.2020.10.596>), were female, postmenopausal, and had histologically or cytologically confirmed invasive, ER-positive metastatic or inoperable locally advanced BC. A valid, centralized cobas[®] PIK3CA Mutation Test result from formalin-fixed paraffin-embedded tissue was required before randomization. Patients had radiologic/objective evidence of BC recurrence or progression while on or within 12 months of the end of adjuvant treatment with an aromatase inhibitor, or progression while on or within 1 month of the end of prior aromatase inhibitor treatment of locally advanced or metastatic BC. Patients had an Eastern Cooperative Oncology Group (ECOG) Performance Status of zero or one and measurable disease via Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or non-measurable, evaluable disease with at least one

evaluable bone lesion via RECIST v1.1. Patients were also candidates for endocrine therapy alone at the time of study entry (per treatment guidelines).

Patients were ineligible if they had received prior fulvestrant, a PI3K inhibitor, a mammalian target of rapamycin inhibitor, or an AKT (protein kinase B) inhibitor. Patients requiring chemotherapy for visceral crisis per their physician's judgment, who had received >1 prior cytotoxic chemotherapy regimen for metastatic BC, or who had HER2-positive disease by local testing were ineligible.

SANDPIPER was approved by an institutional review board and conducted per the principles of the Declaration of Helsinki, International Council for Harmonisation Guidelines, and the laws and regulations of the countries in which it was conducted. All patients provided written informed consent.

Randomization and masking

Patients were randomly assigned 2 : 1 to either the taselesib or placebo arm; patients with *PIK3CA*-mutant tumors or *PIK3CA*-MND tumors (based on tumor tissue) were randomized separately using a permuted-block randomization method.

Stratification factors were visceral disease (visceral versus non-visceral), geographic region [Asia versus Western Europe/USA/Canada/Australia versus the rest of the world (RoW)], and endocrine sensitivity (sensitive versus non-sensitive).

Endocrine sensitivity was defined as either no endocrine treatment in advanced or metastatic BC and 24 months of adjuvant endocrine treatment before recurrence or documented clinical benefit [complete response (CR), partial response (PR), or stable disease 24 weeks] to most recent endocrine treatment in advanced or metastatic BC.

Outcomes

The primary endpoint was investigator-assessed progression-free survival (INV-PFS) in patients with *PIK3CA*-mutant tumors. Secondary endpoints included ORR, overall survival (OS), clinical benefit rate (CBR), duration of objective response (DoR), and PFS by blinded independent central review (BICR-PFS) in patients with *PIK3CA*-mutant tumors. Safety was assessed in all patients who received at least one dose of taselesib/placebo or fulvestrant, regardless of *PIK3CA* mutation status. Exploratory endpoints included efficacy in patients with *PIK3CA*-MND tumors and in patients whose *PIK3CA* mutation status was determined by circulating tumor DNA (ctDNA) analysis. Time to deterioration (TTD) in health-related quality of life (HRQoL) was also assessed.

Safety

Safety was evaluated by monitoring all AEs, standard laboratory abnormalities, and vital signs. AEs were defined and graded per National Cancer Institute — Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.0. 'Group' terms were defined based on the Medical Dictionary for Regulatory Activities (MedDRA; Supplementary Protocol available at <https://doi.org/10.1016/j.annonc.2020.10.596>).

Biomarker assessments

PIK3CA mutation status was determined centrally using the cobas® *PIK3CA* Mutation Test from formalin-fixed paraffin-embedded primary or metastatic tissue, according to the manufacturer's instructions (Roche Molecular Systems, Branchburg, NJ, USA). This test detects the following *PIK3CA* mutations: R88Q, N345K, C420R, E542K, E545A/G/K/D, Q546K/R/E/L, M1043I, H1047L/R/Y, and G1049R. Tumors were classified as '*PIK3CA*-mutant' based on a positive result or '*PIK3CA*-MND' if no mutations were detected.

PIK3CA mutations were also analyzed in plasma ctDNA using the FoundationOne® Liquid assay (Foundation Medicine, Inc., Cambridge, MA) as described previously.¹⁹

Tumor assessments

All known sites of disease were documented at screening (within 28 days before cycle 1, day 1) and reassessed at each subsequent tumor evaluation (every 8 weeks \pm 5 days from the date of randomization). Response assessments were made by the investigator based on physical examinations, computerized tomography scans, or magnetic resonance imaging, and/or bone scans per RECIST v1.1. The same radiographic procedure used to assess disease sites at screening was used throughout the study.

Statistical analysis

Planned enrollment was 600 patients, with a 4 : 1 enrichment of patients with *PIK3CA*-mutant (480 patients) versus *PIK3CA*-MND (120 patients) tumors (exploratory endpoint population). The sample size of 480 patients with *PIK3CA*-mutant tumors was determined based on a power calculation (primary endpoint analysis population). In these patients, approximately 287 INV-PFS events were required to detect the treatment difference under a target HR of 0.59 in PFS (3.1 months of improvement in median PFS) with 95% power at the α two-sided significance level of 1%, assuming a median PFS of 4.5 months in the control arm. One interim INV-PFS efficacy analysis was conducted at 60% of the planned PFS events for the primary analysis.

The intention-to-treat population included all randomized patients regardless of whether they received any amount of the assigned treatment. The primary and secondary efficacy populations comprised patients with *PIK3CA*-mutant tumors only. The safety-evaluable population included all randomized patients who received at least one dose of taselelisib/placebo or fulvestrant regardless of *PIK3CA*-mutation status, with patients allocated to the treatment arm associated with the regimen received.

Median PFS (INV and BICR), OS, and DoR were estimated using the Kaplan—Meier approach in each treatment arm. Cox proportional hazards models were used to estimate the HR with 95% CI.

The Blyth—Still—Casella method was used to estimate the ORR and CBR and the corresponding 95% CI for each treatment arm. The stratified Cochran—Mantel—Haenszel test was used to compare ORR and CBR between treatment arms. The 95% CI for the difference in ORRs and CBRs between the two treatment arms was determined using the normal approximation to the binomial distribution. CBR was defined as CR, PR, or stable

disease lasting 24 weeks. TTD in HRQoL was compared between treatment arms using the stratified Cox proportional hazards model.

RESULTS

Patient characteristics

Between 9 April 2015 and 4 September 2017, 631 patients were randomized to either the taselisib ($n = 417$) or placebo arm ($n = 214$) (Supplementary Figure S2 available at <http://doi.org/10.1016/j.annonc.2020.10.596>). Of the 516 patients with *PIK3CA*-mutant tumors, 176 and 340 were randomized to the placebo and taselisib arms, respectively; the data reported here focus on these patients unless otherwise specified. Baseline characteristics were well balanced between treatment arms (Table 1). Patients were enrolled from Western Europe, USA, Canada, or Australia (49.6%), Asia (15.7%), and RoW (34.7%); a numerically greater proportion of patients in the RoW versus non-RoW had an ECOG PS of one and had received prior tamoxifen in the placebo arm (Supplementary Table S2 available at <https://doi.org/10.1016/j.annonc.2020.10.596>). Median time on study was 10.8 months (range, 1.2-31.7 months) in the placebo arm and 11.2 months (range, 0-30.3 months) in the taselisib arm.

Efficacy

At clinical cutoff (15 October 2017), 67.6% of patients in the placebo arm versus 57.1% in the taselisib arm had experienced a PFS event (Figure 1A). In patients with *PIK3CA*-mutant tumors, the median INV-PFS in the placebo arm was 5.4 months (95% CI, 3.68-7.29) versus 7.4 months (95% CI, 7.26-9.07) in the taselisib arm (stratified HR 0.70; 95% CI, 0.56-0.89; $P = 0.0037$). BICR-PFS was consistent with INV-PFS and confirmed the magnitude of benefit (Figure 1B). Across most subgroups evaluated, results were consistent with the overall *PIK3CA*-mutant cohort with a treatment benefit in favor of the taselisib versus placebo arm (Figure 2).

Exploratory analyses of INV-PFS by geographic region showed a consistent benefit of taselisib versus placebo, except for patients from the RoW (Supplementary Figure S3A; Asia: Supplementary Figure S3B; Western Europe/USA/Canada/Australia: Supplementary Figure S3C available at <https://doi.org/10.1016/j.annonc.2020.10.596>). The RoW accounted for 34.7% of the patients with *PIK3CA*-mutant tumors overall and was the only region with an INV-PFS HR >1 (1.18). Consistent with the lack of INV-PFS benefit, patients in the RoW had a longer median BICR-PFS in the placebo versus taselisib arm compared with patients in other regions (Supplementary Table S3 available at <https://doi.org/10.1016/j.annonc.2020.10.596>).

In patients with *PIK3CA*-MND tumors, median INV-PFS was 4.0 months in the placebo arm and 5.6 months in the taselisib arm (stratified HR 0.69; 95% CI, 0.44-1.08) (Supplementary Figure S4A available at <https://doi.org/10.1016/j.annonc.2020.10.596>). Baseline demographics in patients with *PIK3CA*-MND tumors were generally balanced between arms (Supplementary Table S4 available at <https://doi.org/10.1016/j.annonc.2020.10.596>).

Among patients in the *PIK3CA*-mutant cohort with measurable disease, the objective response (CR or PR) was 16.1% higher in the tasisib arm (28.0%) versus the placebo arm (11.9%; 95% CI, 8.4-23.8) (Table 2). In the placebo arm, 11.9% of patients had a PR versus 27.3% in the tasisib arm (Table 2). Among patients with measurable disease at baseline, the CBR was lower in the placebo arm (37.3%) versus the tasisib arm (51.5%) (Table 2). The median DoR was 7.2 months (95% CI, 6.51-not evaluable) in the placebo arm and 8.7 months (95% CI, 5.72-11.24) in the tasisib arm (Table 2).

In patients with measurable disease in the *PIK3CA*-MND cohort, the ORR was 14.3% in the placebo arm versus 19.7% in the tasisib arm (Supplementary Figure S4B available at <https://doi.org/10.1016/j.annonc.2020.10.596>).

At clinical cutoff, OS data were immature. A total of 116 patients in the *PIK3CA*-mutant cohort had died (placebo arm: 24.4%; tasisib arm: 21.5%) (Table 2).

Safety

Most patients reported at least one AE, regardless of causality (Table 3). The most frequent all-grade AEs were gastrointestinal disorders (placebo arm: 55.4%; tasisib arm: 81.7%). The most common AEs in the tasisib arm (15% of patients) were diarrhea, hyperglycemia, nausea, decreased appetite, fatigue, headache, stomatitis, vomiting, asthenia, and rash (Table 3). Grade 3-5 AEs were experienced by 16.4% and 49.5% of patients in the placebo and tasisib arms, respectively, with diarrhea and hyperglycemia most commonly reported in the tasisib arm (Table 3).

The proportion of serious AEs was lower in the placebo arm versus the tasisib arm (8.9% versus 32.0%, respectively; Table 3). The most frequent serious AEs were gastrointestinal disorders (placebo arm: 0.9%; tasisib arm: 15.1%).

All-grade and serious infection occurred in 23.9% and 0.9% in the placebo arm, respectively (versus 41.8% and 7.5% of patients in the tasisib arm, respectively). Urinary tract infection was most frequently reported, with respiratory tract, gastrointestinal tract, and skin infections also common; no pattern of infection was identified.

Grade 5 AEs were observed in both the placebo (0.5%) and tasisib arms (1.9%) (Table 3). While there was no pattern in the cause of deaths, underlying disease was identified as a factor in several cases.

A lower proportion of patients in the placebo arm experienced AEs leading to tasisib/placebo discontinuation (2.3% versus 16.8% in the tasisib arm) and dose reduction (2.3% versus 36.5% in the tasisib arm) (Table 3).

AEs, including grade 3, serious AEs, and AEs leading to dose discontinuation, reduction, and interruption, were less frequent in the placebo versus tasisib arm in patients with *PIK3CA* mutations when analyzed by geographical region (Supplementary Table S5 available at <https://doi.org/10.1016/j.annonc.2020.10.596>). Relative to Western Europe/USA/Canada/Australia, patients from the RoW experienced fewer grade 3 AEs and AEs leading to tasisib discontinuation in the tasisib arm.

***PIK3CA* ctDNA biomarker assessment**

Of the 631 patients enrolled, 339/598 plasma samples analyzed had detectable *PIK3CA* mutations, with 66 having 2 *PIK3CA* mutations. Overall concordance between tumor and ctDNA *PIK3CA* mutation positivity was 79.7% (Supplementary Tables S6 and S7 available at <https://doi.org/10.1016/j.annonc.2020.10.596>). Where tumors were classified as *PIK3CA*-mutant based on tissue analysis, 78.2% of patients also had detectable *PIK3CA* mutations by ctDNA analysis. Ninety-one patients with *PIK3CA*-mutant tumor tissue had no detectable ctDNA *PIK3CA* mutations (21.8%). Where tumors were classified as *PIK3CA*-MND based on tumor tissue analysis, 86.7% of patients also had no detectable *PIK3CA* mutations by ctDNA analysis. Twelve patients with *PIK3CA*-MND based on tumor tissue analysis had detectable *PIK3CA* mutations by ctDNA analysis (13.3%).

Based on ctDNA analysis, the INV-PFS HRs for patient subgroups with *PIK3CA*-mutant and *PIK3CA*-MND tumors were 0.62 (95% CI, 0.47-0.83) and 0.86 (95% CI, 0.57-1.27), respectively (Figures 3A and 3B; Supplementary Table S8 available at <https://doi.org/10.1016/j.annonc.2020.10.596>). The HR for INV-PFS in the taselesib and placebo arms was higher where patients had one *PIK3CA* mutation (HR 0.68, 95% CI, 0.49-0.93), compared with patients with 2 *PIK3CA* mutations (HR 0.37; 95% CI, 0.18-0.77) (Supplementary Figures S5A and S5B and Supplementary Table S8 available at <https://doi.org/10.1016/j.annonc.2020.10.596>). Similar geographic regional differences were observed with ctDNA analysis (Supplementary Table S9 available at <https://doi.org/10.1016/j.annonc.2020.10.596>).

The frequency of *PIK3CA* mutations across treatment arms did not differ when analyzed by geographical region (Supplementary Table S10 available at <https://doi.org/10.1016/j.annonc.2020.10.596>).

TTD in HRQoL

At clinical cutoff, TTD-HRQoL data were immature. Fifty-eight of 176 (33.0%) and 120/340 (35.3%) patients with *PIK3CA* mutations in the placebo and taselesib arms, respectively, had a deterioration in HRQoL. Median TTD in HRQoL was 6.5 months (95% CI, 3.8-11.1) in the placebo arm versus 8.1 months (95% CI, 7.3-9.7) in the taselesib arm (not statistically significant; stratified HR, 0.84; 95% CI, 0.60-1.16; $P = 0.28$; Supplementary Table S11 available at <https://doi.org/10.1016/j.annonc.2020.10.596>).

DISCUSSION

SANDPIPER was a phase III, double-blind, randomized study of taselesib/placebo plus fulvestrant in patients with ER-positive, HER2-negative, locally advanced or metastatic BC. SANDPIPER met its primary endpoint: the addition of taselesib to fulvestrant showed a statistically significant improvement in INV-PFS in patients with *PIK3CA*-mutant tumors. However, despite this improvement (HR 0.70), addition of taselesib to fulvestrant did not result in a clinically meaningful improvement given the short PFS observed. Taselesib plus fulvestrant had an expected safety profile, but with a higher proportion of discontinuations and dose reductions compared with the placebo arm.

Across most subgroups evaluated for INV-PFS, results were generally consistent with the overall *PIK3CA*-mutant cohort, with a treatment benefit in favor of the tasisib arm. A major exception was the RoW subgroup, where there was no benefit of adding tasisib to fulvestrant (HR 1.18). The reasons for this difference remain unknown and could not be readily explained by differential regional baseline characteristics or safety profiles. There was also no evidence of systemic bias since BICR-PFS analysis confirmed these regional differences.

In the SANDPIPER placebo arm, median INV- and BICR-PFS in patients with *PIK3CA*-mutant tumors were longer than expected based on subgroup analyses from the BELLE-2 and PALOMA-3 studies,^{20,21} and this may have confounded the overall results. The longer median PFS in the placebo arm of SANDPIPER could not be explained by differences in baseline characteristics between treatment arms.

Secondary endpoints, including ORR, CBR, DoR, and BICR-PFS, showed consistent improvement with tasisib plus fulvestrant. OS data are immature at the time of this primary PFS analysis. Tasisib plus fulvestrant led to a numerical but not statistically significant improvement versus placebo in TTD in HRQoL; however, data were immature at the time of primary analysis.

The clinical efficacy of fulvestrant plus alpelisib, a selective inhibitor of PI3K α , was reported in the phase III, randomized, placebo-controlled SOLAR-1 trial, which had a similar patient population to SANDPIPER.²² Both SANDPIPER and SOLAR-1 met their primary endpoints, with statistically significant improvements in INV-PFS in the *PIK3CA*-mutant population (SANDPIPER: HR 0.70; $P=0.0037$; SOLAR-1: HR 0.65; $P=0.001$). However, patients treated with alpelisib plus fulvestrant had a PFS of 11 months (versus 5.7 months with placebo plus fulvestrant), which was longer than the 7.4 months observed in the tasisib arm of SANDPIPER (versus 5.4 months in the placebo arm).²² The Kaplan—Meier PFS curves for the alpelisib plus fulvestrant versus placebo plus fulvestrant arms in SOLAR-1 remained separated, whereas the curves for the tasisib versus placebo arms in SANDPIPER converged, consistent with a clinically more meaningful benefit in SOLAR-1.²² Interestingly, regional variations in PFS were reported in both SOLAR-1 and SANDPIPER: there was no treatment benefit with alpelisib in the Latin American region (9% of patients) or tasisib in the RoW (35% of patients), which included Latin America.²² Direct comparisons of the data should be made with caution given the differential PI3K inhibitor profile of alpelisib versus tasisib and the differing definitions of endocrine sensitivity in the two trials.²²

In our exploratory analysis of plasma collected immediately before enrollment, HR was more favorable for patients who had *PIK3CA* mutations detected by ctDNA analysis versus those detected in tissue (0.62 versus 0.70, respectively). The numerically lower INV-PFS in the placebo arm when *PIK3CA* mutations were detected by ctDNA versus tumor tissue analysis (3.6 versus 5.4 months, respectively) is consistent with the fulvestrant control arm in the BELLE-2 study (hormone receptor-positive, HER2-negative advanced BC; 3.2 versus 4.0 months, respectively),²³ potentially identifying a higher-risk population. Notably, patients with 2 detectable *PIK3CA* mutations by ctDNA analysis had a more favorable

HR for INV-PFS and a higher ORR versus those with a single mutation,²⁴ suggesting that patients with 2 *PIK3CA* mutations may derive a larger clinical benefit from PI3K inhibition.

Taselisib plus fulvestrant had an expected safety profile,^{13,17} with gastrointestinal toxicities and hyperglycemia being the most frequent AEs. Potential new safety signals with a higher frequency in the tselisib arm included infections, alopecia, pyrexia, decreased weight, and dyspepsia. Although there was a higher proportion of AEs leading to study drug discontinuation and dose reduction in the SOLAR-1 alpelisib arm (25.0% and 63.9%, respectively) versus the SANDPIPER tselisib arm (16.8% and 36.5%, respectively), this did not lead to poorer efficacy.²²

In conclusion, SANDPIPER met its primary endpoint; however, tselisib plus fulvestrant has no clinical utility given its safety profile and modest clinical benefit.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We would like to thank the patients, their families, the nurses, the investigators, and the other site staff who participated in this study as well as the SANDPIPER study team. We would also like to thank Dr José Baselga (AstraZeneca, Gaithersburg, MA) and Dr Sunil Verma (AstraZeneca, Gaithersburg, MA) for their contributions during the course of the study, and Surai Jones (Genentech, Inc., South San Francisco, CA, USA) for statistical support. We thank Roche Molecular Diagnostics (Pleasanton, CA, USA) for development of the cobas[®] PIK3CA Mutation Test and support of the SANDPIPER study. F. Hoffmann-La Roche Ltd funded the study, provided study drugs, and was involved in the study design, protocol development, regulatory and ethics approvals, safety monitoring and reporting, data management, and data analysis and interpretation. Support for third-party writing assistance for this manuscript, furnished by Islay Steele, PhD, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd.

FUNDING

This work was supported by F. Hoffmann-La Roche Ltd, Basel, Switzerland (no grant number).

DISCLOSURE

SD reports research grant funding from Novartis US and honoraria from Novartis. JC reports stock or other ownership in MedSIR; honoraria from F. Hoffmann-La Roche Ltd, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, and Merck Sharp & Dohme; fees from a consultancy or advisory role from F. Hoffmann-La Roche Ltd, Celgene, AstraZeneca, Cellectis, Biothera Pharmaceuticals, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Lilly, Polyphor, Servier, Merck Sharp & Dohme, and GSK; research funding to his institution from F. Hoffmann-La Roche Ltd, ARIAD Pharmaceuticals, AstraZeneca, Baxalta GmbH/Servier Affaires, Bayer Healthcare, Eisai, Guardant Health, Merck Sharp & Dohme, Pfizer, PIQUR Therapeutics, Puma Biotechnology, Queen Mary University of London, Seagen; and travel or accommodation expenses from F. Hoffmann-La Roche Ltd, Novartis, Pfizer, Daiichi Sankyo, and Eisai. Y-HI declares no conflicts of interest. VD reports honoraria and fees from a consultancy or advisory role from Pfizer, Novartis, Lilly, F. Hoffmann-La Roche Ltd, AbbVie, Seattle Genetics, AstraZeneca, Daiichi Sankyo, and Merck Sharp & Dohme; and travel, accommodations, or expenses from Pfizer, AstraZeneca, and Novartis. NH has received honoraria for consulting and lectures from Roche and Novartis. IEK reports honoraria from Genentech, AstraZeneca, and Celltrion, fees from a consulting or advisory role from Genentech/Roche, Seattle Genetics, Daiichi Sankyo, MacroGenics, Taiho Pharmaceutical, Context Therapeutics, Novartis, Merck, and Ionis, research funding from Genentech and Pfizer, and employment/leadership/stock and other ownership interests (for an immediate family member) from AMAG Pharmaceuticals. TRW is an employee of Genentech, Inc., and holds stock in F. Hoffmann-La Roche Ltd. NC was previously an employee of Genentech, Inc., and is now employed by CStone Pharmaceuticals, and holds stock in both companies. FS is an employee of Genentech, Inc., holds stock in F. Hoffmann-La Roche Ltd, Exelixis, and Teva, and has patent or intellectual property interests with Exelixis. JYH is an employee of Genentech, Inc., and holds stock in F. Hoffmann-La Roche

Ltd. JH was an employee of F. Hoffmann-La Roche Ltd/Genentech, Inc., and holds stock in F. Hoffmann-La Roche Ltd/Genentech, Inc. MDL reports honoraria from Novartis, F. Hoffmann-La Roche Ltd, Pfizer, Celgene, Eisai, and Amgen; fees for a consulting or advisory role from Novartis, F. Hoffmann-La Roche Ltd, Pfizer, Eisai, Celgene, Lilly, Genomic Health, MSD Oncology, and Amgen; research funding from F. Hoffmann-La Roche Ltd, Eisai, and Italfarmaco; and fees from speakers' bureau from Novartis and F. Hoffmann-La Roche Ltd. SS reports fees for advisory boards from F. Hoffmann-La Roche Ltd, Novartis, AstraZeneca, Lilly, and Pfizer; fees for speakers' bureau from F. Hoffmann-La Roche Ltd, Novartis, AstraZeneca, Lilly, and Pfizer; and fees for travel, accommodations, or expenses from F. Hoffmann-La Roche Ltd, Novartis, Pfizer, Lilly, Amgen, AstraZeneca, and Pierre Fabre. PD reports research funding from F. Hoffmann-La Roche Ltd and Novartis and NIH/NCI core grant funding (P30CA008798). WJ reports fees for a consulting or advisory role from AstraZeneca, Eisai, Lilly France, MSD, Pfizer, F. Hoffmann-La Roche Ltd, and Novartis; research funding from AstraZeneca; and travel, accommodations, or expenses from AstraZeneca, Chugai Pharma, Eisai, Lilly France, Pfizer, GSK, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sanofi-Aventis. All authors received support for third-party writing assistance for this manuscript from F. Hoffmann-La Roche Ltd.

REFERENCES

1. Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease. *Cell*. 2017;170(4):605–635. [PubMed: 28802037]
2. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. *Science*. 2004;304(5670):554. [PubMed: 15016963]
3. Zhang Y, Kwok-Shing Ng P, Kucherlapati M, et al. A pan-cancer proteogenomic atlas of PI3K/AKT/mTOR pathway alterations. *Cancer Cell*. 2017;31(6):820–832.e823. [PubMed: 28528867]
4. Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. *Nat Med*. 2017;23(6):703–713. [PubMed: 28481359]
5. Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway? *Nat Rev Clin Oncol*. 2018;15(5):273–291. [PubMed: 29508857]
6. Arthur LM, Turnbull AK, Renshaw L, et al. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. *Breast Cancer Res Treat*. 2014;147(1):211–219. [PubMed: 25104442]
7. Bosch A, Li Z, Bergamaschi A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. *Sci Transl Med*. 2015;7(283):283ra251.
8. Toska E, Osmanbeyoglu HU, Castel P, et al. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D. *Science*. 2017;355(6331):1324–1330. [PubMed: 28336670]
9. Olivero AG, Heffron TP, Baumgardner M, et al. Discovery of GDC-0032: a beta-sparing PI3K inhibitor active against PIK3CA mutant tumors. *Cancer Res*. 2013;73(suppl 8). Abstract DDT02-01 (and associated oral presentation).
10. Ndubaku CO, Heffron TP, Staben ST, et al. Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxa zepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β -sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity. *J Med Chem*. 2013;56(11):4597–4610. [PubMed: 23662903]
11. Wallin JJ, Edgar KA, Guan J, et al. The PI3K inhibitor GDC-0032 is selectively potent against PIK3CA mutant breast cancer cell lines and tumors. *Cancer Res*. 2013;73(suppl 24). Abstract P2-17-01 (and associated poster presentation).
12. Edgar KA, Song K, Schmidt S, et al. The PI3K inhibitor, taselisib (GDC-0032), has enhanced potency in PIK3CA mutant models through a unique mechanism of action. *Cancer Res*. 2016;76(suppl 14). Abstract 370 (and associated poster presentation).
13. Juric D, Krop I, Ramanathan RK, et al. Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. *Cancer Discov*. 2017;7(7):704–715. [PubMed: 28331003]
14. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. *J Clin Oncol*. 2012;30(3):282–290. [PubMed: 22162589]

15. Gopal AK, Kahl BS, de Vos S, et al. PI3K δ inhibition by idelalisib in patients with relapsed indolent lymphoma. *N Engl J Med*. 2014;370(11):1008–1018. [PubMed: 24450858]
16. Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. *Clin Cancer Res*. 2015;21(1):77–86. [PubMed: 25370471]
17. Dickler MN, Saura C, Richards DA, et al. Phase II study of taselisib (GDC-0032) in combination with fulvestrant in patients with HER2-negative, hormone receptor-positive advanced breast cancer. *Clin Cancer Res*. 2018;24(18):4380–4387. [PubMed: 29793946]
18. Saura C, Hlauschek D, Oliveira M, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Oncol*. 2019;20(0): 1226–1238. [PubMed: 31402321]
19. Clark TA, Chung JH, Kennedy M, et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. *J Mol Diagn*. 2018;20(5):686–702. [PubMed: 29936259]
20. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*. 2016;17(4):425–439. [PubMed: 26947331]
21. Baselga J, Im S-A, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2017;18(7):904–916. [PubMed: 28576675]
22. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *N Engl J Med*. 2019;380(20):1929–1940. [PubMed: 31091374]
23. Baselga J, Im SA, Iwata H, et al. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2017;18:904–916. [PubMed: 28576675]
24. Vasan N, Razavi P, Johnson JL, et al. Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K α inhibitors. *Science*. 2019;366(6466):714–723. [PubMed: 31699932]




Figure 1. Kaplan—Meier plots for PFS in patients with *PIK3CA*-mutant tumors: (A) investigator-assessed PFS; (B) BICR-PFS.

PFS was defined as the time from randomization to first disease progression as determined by the investigator using RECIST v1.1, or death from any cause.

BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; INV, investigator-assessed; PFS, progression-free survival; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.




Figure 2. Forest plot of investigator-assessed PFS in patients with *PIK3CA*-mutant tumors.

PFS was defined as the time from randomization to first disease progression as determined by the investigator using RECIST v1.1, or death from any cause.

CI, confidence interval; CDK, cyclin-dependent kinase; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HR, hazard ratio; IxRS, Interactive Voice/Web Response System; MBC, metastatic breast cancer; PFS, progression-free survival; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1.




Figure 3. Kaplan—Meier plots for INV-PFS in patients with *PIK3CA* mutation status determined by ctDNA analysis: (A) patients with *PIK3CA*-mutant tumors and (B) patients with MND.

CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; INV, investigator-assessed; MND, mutation not detected; PFS, progression-free survival; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

Table 1.Baseline demographic and disease characteristics in patients with *PIK3CA*-mutant tumors

	Placebo + fulvestrant (n = 176)	Taselisib + fulvestrant (n = 340)
Age in years, median (range)	61 (39-85)	60 (32-84)
ECOG PS		
0	93 (52.8)	185 (54.4)
1	83 (47.2)	155 (45.6)
Visceral disease ^a	103 (58.5)	201 (59.1)
Bone-only disease	32 (18.2)	70 (20.6)
Bone metastasis	127 (72.2)	267 (78.5)
Measurable disease	134 (76.1)	264 (77.6)
Endocrine sensitivity ^a	129 (73.3)	251 (73.8)
Prior endocrine therapy		
Prior adjuvant endocrine therapy	120 (68.2)	203 (59.7)
Prior endocrine therapy for MBC	121 (68.8)	254 (74.7)
Prior tamoxifen (regardless of setting)	86 (48.9)	168 (49.4)
Prior CDK4/6 inhibitor	3 (1.7)	12 (3.5)
Prior chemotherapy		
Prior chemotherapy in MBC	49 (27.8)	109 (32.1)
Prior systemic therapy in MBC	128 (72.7)	265 (77.9)
Number of regimens in MBC, median (25%, 75%)	1 (0, 2)	1 (1, 2)
Range	0-6	0-5
Region ^a		
Western Europe/USA/Canada/Australia	86 (48.9)	170 (50.0)
Asia	29 (16.5)	52 (15.3)
Rest of the world	61 (34.7)	118 (34.7)

Data are n (%) unless otherwise specified.

CDK, cyclin-dependent kinases; ECOG PS, Eastern Cooperative Oncology Group Performance Status; MBC, metastatic breast cancer; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.^aStratification factor.

Table 2.Secondary efficacy in patients with *PIK3CA*-mutant tumors

	Placebo + fulvestrant	Taselisib + fulvestrant
Patients with measurable disease	(<i>n</i> = 134)	(<i>n</i> = 264)
Responders	16 (11.9%)	74 (28.0%)
Difference in response rates (95% CI)	16.1 (8.4-23.8)	
<i>P</i> value	0.0002	
(Cochran–Mantel–Haenszel)		
CR	0	2 (0.8%)
PR	16 (11.9%)	72 (27.3%)
CBR	50 (37.3%)	136 (51.5%)
Patients with and without measurable disease	(<i>n</i> = 176)	(<i>n</i> = 340)
CBR	73 (41.5%)	185 (54.4%)
DoR	(<i>n</i> = 16)	(<i>n</i> = 74)
Median, months (95% CI)	7.2 (6.51-NE)	8.7 (5.72-11.24)
OS	(<i>n</i> = 176)	(<i>n</i> = 340)
Events	43 (24.4%)	73 (21.5%)

CBR was defined as objective response or no disease progression for 24 weeks since randomization; confirmation not needed for CR and PR.

CI, confidence interval; CBR, clinical benefit rate; CR, complete response; DoR, duration of objective response; NE, not evaluable; OS, overall survival; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PR, partial response.

Safety summary, including the most frequent all-grade AEs and grade 3 AEs (regardless of causality; safety-evaluable patients regardless of *PIK3CA*-mutant tumor status)

Table 3.

Safety summary	Placebo + fulvestrant (n = 213)	Taselisib + fulvestrant (n = 416)
All-grade AEs	191 (89.7)	397 (95.4)
All-grade selected AEs (associated with PI3K inhibition) ^a	86 (40.4)	356 (85.6)
Grade 3 AEs	35 (16.4)	206 (49.5)
Grade 3 selected AEs (associated with PI3K inhibition) ^a	4 (1.9)	130 (31.3)
SAEs ^b	19 (8.9)	133 (32.0)
Grade 5 AEs	1 (0.5) ^c	8 (1.9) ^d
Dose modifications		
AEs leading to telasib/placebo discontinuation	5 (2.3)	70 (16.8) ^e
AEs leading to telasib/placebo dose interruption	24 (11.3)	169 (40.6)
AEs leading to telasib/placebo dose reduction	5 (2.3)	152 (36.5)
AEs leading to fulvestrant discontinuation	5 (2.3)	18 (4.3)
AEs leading to fulvestrant interruption	10 (4.7)	57 (13.7)
Most frequent any-grade AEs in 10% in the telasib arm		
Diarrhea ^f	42 (19.7)	250 (60.1)
Hyperglycemia ^f	20 (9.4)	168 (40.4)
Nausea	52 (24.4)	142 (34.1)
Decreased appetite	22 (10.3)	110 (26.4)
Fatigue	38 (17.8)	101 (24.3)
Headache	25 (11.7)	84 (20.2)
Stomatitis ^f	18 (8.5)	138 (33.2)
Vomiting	24 (11.3)	78 (18.8)
Asthenia	39 (18.3)	77 (18.5)
Rash ^f	24 (11.3)	105 (25.2)
Cough	28 (13.1)	54 (13.0)

Safety summary	Placebo + fulvestrant (<i>n</i> = 213)	Taselisib + fulvestrant (<i>n</i> = 416)
Back pain	24 (11.3)	54 (13.0)
Abdominal pain	19 (8.9)	51 (12.3)
Dry mouth	16 (7.5)	51 (12.3)
Arthralgia	27 (12.7)	48 (11.5)
Alopecia	6 (2.8)	47 (11.3)
Pruritus	16 (7.5)	46 (11.1)
Pyrexia	7 (3.3)	44 (10.6)
Dyspnea	17 (8.0)	43 (10.3)
Most frequent grade 3 AEs in 1% in the taselisib arm		
Diarrhea ^f	2 (0.9)	48 (11.5)
Hyperglycemia ^f	1 (0.5)	45 (10.8)
Rash ^f	–	16 (3.8)
Stomatitis ^f	–	15 (3.6)
Colitis ^f	–	13 (3.1)
Hypertension	7 (3.3)	10 (2.4)
Dehydration	1 (0.5)	8 (1.9)
ALT increase	–	8 (1.9)
Lipase increased	2 (0.9)	7 (1.7)
Neutropenia	2 (0.9)	7 (1.7)
Vomiting	2 (0.9)	7 (1.7)
Pneumonia	–	7 (1.7)
Pneumonitis ^f	1 (0.5)	7 (1.7)
AST increase	1 (0.5)	6 (1.4)
Sepsis	1 (0.5)	5 (1.2)
Diarrhea infectious	–	5 (1.2)
Hypokalemia	–	5 (1.2)

Data are *n* (%).

AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PI3K, phosphatidylinositol 3-kinase; *PIK3CA*, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; SAE, serious adverse event.

^g Selected toxicities of interest for taselisib included diarrhea, colitis, pneumonitis, rash, stomatitis, and hyperglycemia.

^h SAE: includes events that are fatal, life-threatening, require or prolong hospitalization, are considered a significant medical event (investigator judgment), or result in significant disability.

^c Pneumonitis.

^d Alcoholic pancreatitis, acute kidney injury/sepsis, acute respiratory failure, respiratory tract infection, unexplained death (2), hepatotoxicity, myocardial infarction.

^e 51.4% of patients discontinued taselisib due to gastrointestinal toxicities, with diarrhea being the most frequent reason.

^f Frequencies of selected AEs are based on 'group' terms of relevant events associated with taselisib, not preferred terms. Group terms are defined in the Supplementary materials available at <https://doi.org/10.1016/j.jannonc.2020.10.596>.